…
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional foods, as well as manufacturing, marketing, and sale of science-based health and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company is based in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -11.06M | -12.90M | -12.56M | -11.24M | -9.83M |
| Net income | -11.13M | -12.91M | -12.56M | -11.24M | -9.83M |
| Selling general administrative | 19.14M | 14.67M | 12.08M | 9.35M | 4.76M |
| Gross profit | 20.48M | 13.94M | 5.63M | 1.22M | 0.67M |
| Reconciled depreciation | 1.62M | 1.25M | 0.84M | 0.71M | 0.39M |
| Ebit | - | -6.99M | -9.97M | -10.61M | -8.49M |
| Operating income | -5.58M | -6.99M | -9.97M | -10.61M | -8.49M |
| Interest expense | 2.72M | 4.74M | 1.96M | 1.40M | 0.81M |
| Tax provision | 0.08M | 0.01M | 0.00M | - | - |
| Interest income | 0.05M | 0.00M | - | - | 0.00M |
| Net interest income | -3.65M | -5.43M | -2.10M | -1.49M | -0.85M |
| Total revenue | 34.51M | 25.19M | 12.67M | 5.50M | 2.10M |
| Total operating expenses | 40.08M | 32.18M | 22.64M | 16.11M | 10.59M |
| Cost of revenue | 14.03M | 11.25M | 7.04M | 4.28M | 1.43M |
| Total other income expense net | -1.83M | -0.48M | -0.50M | 0.86M | -0.48M |
| Net income from continuing ops | -11.13M | -12.91M | -12.56M | -11.24M | -9.83M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 47.66M | 25.00M | 15.00M | 9.39M | 10.21M |
| Total liab | 22.22M | 23.67M | 29.86M | 15.32M | 7.35M |
| Total stockholder equity | 25.45M | 1.33M | -14.85M | -5.93M | 2.85M |
| Other current liab | 0.45M | 1.14M | 0.53M | - | 0.64M |
| Capital stock | 133.00M | 97.75M | 68.65M | 65.01M | 62.56M |
| Retained earnings | -107.55M | -96.42M | -83.50M | -70.94M | -59.70M |
| Cash | 23.02M | 2.39M | 5.36M | 1.74M | 4.12M |
| Total current liabilities | 7.68M | 14.26M | 26.47M | 11.52M | 2.92M |
| Net debt | - | 1.51M | 15.18M | 6.81M | - |
| Short long term debt | 0.15M | 3.90M | 20.53M | 8.55M | - |
| Total current assets | 30.50M | 7.86M | 9.05M | 4.32M | 5.67M |
| Net receivables | 1.98M | 1.12M | 0.81M | 0.55M | 0.39M |
| Long term debt | 2.42M | - | - | - | - |
| Inventory | 4.56M | 3.65M | 2.47M | 1.38M | 0.93M |
| Accounts payable | 2.63M | 3.52M | 1.78M | 1.07M | 0.88M |
| Non currrent assets other | 0.43M | 0.37M | 0.18M | 0.16M | 0.18M |
| Non current assets total | 17.16M | 17.14M | 5.95M | 5.07M | 4.54M |
| Capital lease obligations | 11.54M | 9.91M | 1.81M | 2.01M | 2.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -3.03M | -1.47M | -1.26M | -1.64M |
| Net borrowings | 5.25M | 2.04M | 13.15M | 7.30M | -0.33M |
| Total cash from financing activities | 30.19M | 6.78M | 13.56M | 8.14M | 10.77M |
| Net income | -11.13M | -12.91M | -12.56M | -11.24M | -9.83M |
| Change in cash | 20.60M | -2.93M | 3.56M | -2.36M | 2.34M |
| Begin period cash flow | 2.39M | 5.36M | 1.74M | 4.12M | 1.78M |
| End period cash flow | 23.02M | 2.39M | 5.36M | 1.74M | 4.12M |
| Total cash from operating activities | -7.23M | -6.68M | -8.52M | -9.24M | -6.79M |
| Issuance of capital stock | 18.26M | 4.33M | 0.00M | 0.00M | 7.47M |
| Depreciation | 1.62M | 1.25M | 0.84M | 0.71M | 0.39M |
| Change to inventory | -0.90M | -1.19M | -1.09M | -0.45M | -0.83M |
| Change to account receivables | -0.86M | -0.31M | -0.26M | -0.16M | -0.17M |
| Capital expenditures | 2.35M | 2.83M | 1.47M | 1.26M | 1.64M |
| Change in working capital | -1.94M | -0.56M | 0.76M | -0.31M | -0.10M |
| Stock based compensation | 0.60M | 0.60M | 0.56M | 1.35M | 3.37M |
| Other non cash items | 3.63M | 1.02M | 0.87M | 0.12M | -1.26M |
| Free cash flow | -9.58M | -9.52M | -10.00M | -10.50M | -8.43M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BHST BioHarvest Sciences Inc. Common Stock |
0.01 0.82% |
1.23 | - | 169.49 | 2.90 | 4.01 | 2.70 | -10.25 |
| NSRGF Nestle SA |
-1.84 1.77% |
102.15 | 26.86 | 18.76 | 3.13 | 7.10 | 3.81 | 21.70 |
| NSRGY Nestle SA ADR |
-0.80 0.78% |
102.21 | 26.82 | 18.66 | 3.18 | 7.07 | 3.81 | 21.70 |
| DANOY Danone PK |
-0.17 1.11% |
15.18 | 24.23 | 17.64 | 1.88 | 2.57 | 1.88 | 11.70 |
| GPDNF Danone S.A |
- -% |
76.59 | 20.30 | 14.75 | 1.65 | 2.24 | 1.76 | 10.92 |
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional foods, as well as manufacturing, marketing, and sale of science-based health and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company is based in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Dr. Zaki Rakib Ph.D. | Co-Founder, Executive Chairman & President | 1959 |
| Mr. Ilan Sobel | Chief Executive Officer | NA |
| Dr. Yochi Hagay Ph.D. | Co-Founder, CTO & Member of Scientific Advisory Board | 1958 |
| Dr. Ilana Belzer Ph.D. | Chief Operating Officer | 1960 |
| Mr. David K. Ryan | VP of Investor Relations & Secretary | 1967 |
| Dr. Brian S. Cornblatt | Chief Medical Officer & Member of Scientific Advisory Board | NA |
| Ms. Bar Dichter | Chief Financial Officer | NA |
| Mr. Matthew Joseph Zrebiec | Vice President of Business Development | NA |
| Dr. Yoheved Hagay Ph.D. | Co-Founder, CTO & Member of Scientific Advisory Board | 1958 |
| Dr. Malkit Azachi Ph.D. | Vice President of Research & Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.